Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (3) J. Venom. Anim. Toxins incl. Trop. Dis. (1) Autor Vigani,Aline Gonzalez (4) Tozzo,Raquel (2) Abati,Paulo Afonso Martins (1) Delicio,Adriane Maira (1) Fais,Viviane (1) Feltrin,Adriana (1) Genari,Flavia (1) Gonçales Jr,Fernando L (1) Gonçales Jr,Fernando Lopes (1) Gonçales,Eduardo SL (1) Gonçales,Eduardo Sellan (1) Gonçales,Neiva Sellan (1) Lazarini,Maria SK (1) Lazarini,Maria Silvia Kroll (1) Oliveira,Alexandre Macedo de (1) Pavan,Maria HP (1) Pavan,Maria Helena Postal (1) Mais... Palavra-chave HBsAg (1) HIV (1) Hemodialysis (1) Hepatitis B (1) Hepatitis C (1) Hepatitis C virus (1) Interferon (1) Interferons (1) Peginterferon (1) Ribavirin (1) Treatment (1) Treatment outcome (1) Mais... Tipo do documento Info:eu-repo/semantics/report (2) Info:eu-repo/semantics/article (1) Info:eu-repo/semantics/other (1) Ano 2013 (1) 2012 (1) 2010 (1) 2007 (1) País Brazil (4) Idioma Inglês (4)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 4 Primeira ... 1 ... Última Adverse event management BJID Vigani,Aline Gonzalez. Tipo: Info:eu-repo/semantics/other Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000700020 Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C BJID Vigani,Aline Gonzalez; Pavan,Maria HP; Tozzo,Raquel; Gonçales,Eduardo SL; Lazarini,Maria SK; Oliveira,Alexandre Macedo de; Gonçales Jr,Fernando L. Hemodialysis patient with chronic HCV infection,who was started on monotherapy with interferon.Qualitative HCV RNA remained positive at 12 weeks of treatment; ribavirin was associated. HCV RNA was negative at week 24 and treatment was extended to 72 weeks. HCV RNA negative six months after treatment. Tipo: Info:eu-repo/semantics/report Palavras-chave: Hepatitis C virus; Hemodialysis; Treatment; Interferon; Ribavirin. Ano: 2010 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702010000200016 Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report J. Venom. Anim. Toxins incl. Trop. Dis. Delicio,Adriane Maira; Abati,Paulo Afonso Martins; Vigani,Aline Gonzalez. Hepatitis B virus (HBV) infects from 6 to 14% of HIV-infected individuals. Concurrent HIV/HBV infection occurs due to the overlapping routes of transmission, particularly sexual and parenteral. HIV-infected patients that have acute hepatitis B have six times greater risk of developing chronic hepatitis B, with higher viral replication, rapid progression to end-stage liver disease and shorter survival. The coinfection is also associated with poor response to hepatitis B treatment with interferon-alpha and increased liver toxicity to the antiretroviral therapy. Herein, we describe the case of a 35-year-old man who engages in sex with men and presented with newly diagnosed HIV-1, serological markers for acute hepatitis B and progression to chronic hepatitis B... Tipo: Info:eu-repo/semantics/report Palavras-chave: HIV; Hepatitis B; HBsAg; Peginterferon. Ano: 2013 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992013000100503 Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3 BJID Vigani,Aline Gonzalez; Gonçales,Eduardo Sellan; Pavan,Maria Helena Postal; Genari,Flavia; Tozzo,Raquel; Lazarini,Maria Silvia Kroll; Fais,Viviane; Feltrin,Adriana; Gonçales,Neiva Sellan; Gonçales Jr,Fernando Lopes. BACKGROUND: Pegylated interferon (Peg-IFN) and standard interferon (IFN) play a significant role in the treatment of hepatitis C virus (HCV) infection. Biosimilar standard IFN is widely available in Brazil for the treatment of HCV infection genotypes 2 or 3, but its efficacy compared to Peg-IFN is unknown. OBJECTIVE: To compare the sustained virological response (SVR) rates following treatment with biosimilar standard IFN plus ribavirin (RBV) versus Peg-IFN plus RBV in patients with HCV genotypes 2 or 3 infection. METHODS: A retrospective cohort study was conducted in patients with HCV genotypes 2 or 3 infection treated with biosimilar standard IFN plus RBV or with Peg-IFN plus RBV. SVR rates of the two treatments were compared. RESULTS: From January 2005... Tipo: Info:eu-repo/semantics/article Palavras-chave: Interferons; Hepatitis C; Treatment outcome. Ano: 2012 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702012000300003 Registros recuperados: 4 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco